Abimbola Farinde, Pharm.D., is a clinical pharmacist specialist with specializations in psychopharmacology and geriatrics.
The Food and Drug Administration’s (FDA) approval of Abraxane, a solvent-free chemotherapy agent used for the treatment of late-stage pancreatic cancer was largely based on the findings from a randomized clinical trial that included 861 participants that were assigned either to receive Abraxane plus gemcitabine or gemcitabine as monotherapy.